117 related articles for article (PubMed ID: 30095329)
1. Role of Computationally Evaluated Target Specificity in the Hepatotoxicity of Gapmer Antisense Oligonucleotides.
Kasuya T; Kugimiya A
Nucleic Acid Ther; 2018 Oct; 28(5):312-317. PubMed ID: 30095329
[TBL] [Abstract][Full Text] [Related]
2. Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.
Kasuya T; Hori S; Watanabe A; Nakajima M; Gahara Y; Rokushima M; Yanagimoto T; Kugimiya A
Sci Rep; 2016 Jul; 6():30377. PubMed ID: 27461380
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice.
Kakiuchi-Kiyota S; Koza-Taylor PH; Mantena SR; Nelms LF; Enayetallah AE; Hollingshead BD; Burdick AD; Reed LA; Warneke JA; Whiteley LO; Ryan AM; Mathialagan N
Toxicol Sci; 2014 Mar; 138(1):234-48. PubMed ID: 24336348
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
[TBL] [Abstract][Full Text] [Related]
5. Fine-tuning of ENA gapmers as antisense oligonucleotides for sequence-specific inhibition.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Oligonucleotides; 2007; 17(3):291-301. PubMed ID: 17854269
[TBL] [Abstract][Full Text] [Related]
6. Mind the Gapmer: Implications of Co-transcriptional Cleavage by Antisense Oligonucleotides.
Maranon DG; Wilusz J
Mol Cell; 2020 Mar; 77(5):932-933. PubMed ID: 32142690
[TBL] [Abstract][Full Text] [Related]
7. Development of a Method for Profiling Protein Interactions with LNA-Modified Antisense Oligonucleotides Using Protein Microarrays.
Kakiuchi-Kiyota S; Whiteley LO; Ryan AM; Mathialagan N
Nucleic Acid Ther; 2016 Apr; 26(2):93-101. PubMed ID: 26643897
[TBL] [Abstract][Full Text] [Related]
8. RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides.
Hori SI; Mitsuoka Y; Kugimiya A
Nucleic Acid Ther; 2019 Feb; 29(1):44-50. PubMed ID: 30508397
[TBL] [Abstract][Full Text] [Related]
9. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of Long Noncoding RNA Plasmacytoma Variant Translocation 1 with Antisense Locked Nucleic Acid GapmeRs Exerts Tumor-Suppressive Functions in Human Acute Erythroleukemia Cells Through Downregulation of
Salehi M; Sharifi M; Bagheri M
Cancer Biother Radiopharm; 2019 Aug; 34(6):371-379. PubMed ID: 30141968
[No Abstract] [Full Text] [Related]
11. Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus.
Okamoto S; Echigoya Y; Tago A; Segawa T; Sato Y; Itou T
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834294
[TBL] [Abstract][Full Text] [Related]
12. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
[TBL] [Abstract][Full Text] [Related]
13. Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice.
Hagedorn PH; Pontoppidan M; Bisgaard TS; Berrera M; Dieckmann A; Ebeling M; Møller MR; Hudlebusch H; Jensen ML; Hansen HF; Koch T; Lindow M
Nucleic Acids Res; 2018 Jun; 46(11):5366-5380. PubMed ID: 29790953
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
Iwashita S; Shoji T; Koizumi M
Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
[TBL] [Abstract][Full Text] [Related]
15. Chemical modification study of antisense gapmers.
Stanton R; Sciabola S; Salatto C; Weng Y; Moshinsky D; Little J; Walters E; Kreeger J; DiMattia D; Chen T; Clark T; Liu M; Qian J; Roy M; Dullea R
Nucleic Acid Ther; 2012 Oct; 22(5):344-59. PubMed ID: 22852836
[TBL] [Abstract][Full Text] [Related]
16. Use of GapmeRs for gene expression knockdowns in human primary resting CD4+ T cells.
Abewe H; Deshmukh S; Mukim A; Beliakova-Bethell N
J Immunol Methods; 2020 Jan; 476():112674. PubMed ID: 31629740
[TBL] [Abstract][Full Text] [Related]
17. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP
Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045
[TBL] [Abstract][Full Text] [Related]
18. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
19. Invention and Early History of Gapmers.
Lim KRQ; Yokota T
Methods Mol Biol; 2020; 2176():3-19. PubMed ID: 32865779
[TBL] [Abstract][Full Text] [Related]
20. Tips for Successful lncRNA Knockdown Using Gapmers.
Lennox KA; Behlke MA
Methods Mol Biol; 2020; 2176():121-140. PubMed ID: 32865787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]